Personalized Medicine Market - Growing Advances in Genomic and Proteomic Science Over the Past Decade Which Has Given A Boost to The Development
Personalized Medicine Market Analysis
According to Verified Market Research, the Global Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of 10.67% from 2019-2026 and reach USD 217.90 Billion by 2026.
What is Personalized Medicine Market?
Advancements in science and technology are fluctuating, especially the way we describe the disease, develop drugs, and recommend treatments. The concept of personalized medicine has emerged with growing advances in genomic and proteomic science over the past decade which has given a boost to the development of “targeted” diagnostics and therapeutics that influence knowledge of an individual’s genetic makeup to construct a more personalized approach to healthcare. The advent and sustained growth of personalized medicine will enhance fundamental changes at many different levels in the future of health care and health systems.
Personalized medicine can be defined as a type of treatment which focuses on the individual physiognomies of each patient. Personalized medicine possesses a huge prospective in leading the healthcare industry with strong modifications and alterations with prime emphasis on the understanding & management of diseases integrated with advanced analytics, patient data, tailored medicines, and other possibilities.
Free PDF Sample of the Report Illustrating New Advancement - http://bit.ly/Personalized-Med
Personalized Medicines are often referred to as the right treatment for the right person at the right moment. According to Federal Drug Administration (FDA), the main objective of personalized medicine is to “streamline clinical decision-making by distinguishing in advance those patients most likely to benefit from a given treatment from those who will incur a cost and suffer side effects without gaining benefit”.
The above-mentioned data is compiled using information from former editions of PMC’s Case for Personalized Medicine (2008–2014) with 2016 data from FDA’s Table of Pharmacogenomic Biomarkers in Drug Labeling. This suggests that the emergence of personalized medicines has elevated the adoption rate and is expected to increase even more owing to the drivers of the market as mentioned below.
Personalized Medicine Market Outlook
The growing dominance of various types of cancer, affordability of personalized medicine therapy in cancer drugs and various other disease indications are expected to fuel the market for Personalized Medicine in the global market. According to the World Health Organization, Cancer is the second leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Since personalized medicine has been helping target cancerous tissues, the scope of personalized medicine is expected to grow exponentially over the forecast period. Apart from this, lesser side effects and high adoption rate in developed markets will also boost the market for Personalized Medicine in the global market. However, every treatment has its own pros and cons. Personalized Medicine to has various challenges. Few of them are listed below:
A survey was conducted among the healthcare and pharmaceutical executives regarding precision and personalized medicines and they claimed that unstable/non-secure legal and regulatory framework was expected to be most popular restraints in the market as the personalized medicine is a relatively new concept with similar applications as precision medicine which could slow down the market growth.
Global Personalized Medicine Market Segmentation
The Global Personalized Medicine Market is classified on the basis of Product, Application, and Region. The gist of breaking down the market into various segments is to gather information about various aspects of the market. On the basis of Product, the market is bifurcated on the basis of Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Nutrition & Wellness, and Personalized Medical Care. The personalized medicine therapeutics is expected to dominate in the market. The reason for this could be the rise in the incidence rate of various types of cancers.
In terms of Application, the market study encompasses various aspects such as cancer management, infectious diseases, central nervous system (CNS) disorders, blood transfusion safety, coagulation therapy, diabetes, autoimmune diseases, cardiovascular diseases, neurology, and psychiatry. The need to control the incidence rates of cancer is expected to boost the cancer management segment making it hold the largest share in the market.
Due to huge investments in healthcare society, the market for personalized medicine is expected to be dominated by North America region followed by Europe. The Asia Pacific is accounted to be the fastest growing market owing to the ongoing research and legal initiatives in the healthcare industry.
Personalized Medicine Market Competitive Landscape
The “Personalized Medicine Market” study report offers a valuable insight with an emphasis on the global market including some of the major players such as Abbott Laboratories, Merck & Co., Inc., AstraZeneca, Pfizer, Inc., GlaxoSmithKline PLC., Novartis AG, Amgen, Inc., Bayer AG, Mylan N.V. and Eli Lilly. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally. Some of the key developments of the major companies that are involved in the Global Personalized Medicine Market are as follows:
|Qiagen Inc.||Expansion & Investment||QIAGEN N.V. announced that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved the therascreen® EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer’s VIZIMPRO® (dacomitinib) for EGFR gene mutation-positive, inoperable or recurrent non-small cell lung cancer|
|Pfizer Inc.||Merger & Acquisitions||Pfizer Inc. and GlaxoSmithKline PLC announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands|
Brochure for Current Industry Analysis - http://bit.ly/Personalized-Med
With growing investments in the healthcare sector and raising awareness about personalized medicine, the growth rate is expected to grow significantly over the forecast period. Apart from this, there were several trends which were witnessed in the global market. They are as follows:
• The focus of personalized medicine has finally shifted beyond oncology. Various new companion diagnostic (CDx) and biomarkers for non-oncology therapeutic areas have been discovered.
• Modernization driven lifestyle has enabled personalized medicine and precision medicine to couple with healthcare big data in order to uplift preventive care for chronic disease management as computer-aided drug design and next-generation ultra-high-throughput sequencing methods quickly generate massive amounts of data.
• Personalized medicine will boost healthcare consumerism as with flourishing consumer engagement movement, people are more interested in healthcare information and want to dynamically contribute to the healthcare decision-making process.